Investigational drug · Phase 2
BAY 3713372
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for MTAP-deleted Solid Tumors.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BAY 3713372"
First trial start
2025
Mar 21, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BAY 3713372", any sponsor or status.
Conditions studied
As listed on its trial records.
- MTAP-deleted Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BAY 3713372" as an intervention, largest first.
BayerBayer (BAYRY)
NCT06914128 · 450 participants (planned) · Start Mar 21, 2025 · Primary completion Jun 18, 2029
Drug: BAY 3713372 · For: MTAP-deleted Solid Tumors
Sites: Birmingham, Alabama; Duarte, California; Los Angeles, California · 62 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for MTAP-deleted Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bayer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.